InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
October 12, 2021 07:30 ET
|
InflaRx N.V.
Study has enrolled 369 patients across 9 countriesTopline results expected to be available in Q1 2022 JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage...
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
September 08, 2021 07:30 ET
|
InflaRx N.V.
InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions – including reductions of draining...
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum
August 10, 2021 07:30 ET
|
InflaRx N.V.
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesionTreatment was well tolerated; no adverse events associated with dose...
InflaRx to Present at the BTIG Virtual Biotechnology Conference
August 06, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will...
InflaRx Reports Second Quarter 2021 Financial & Operating Results
August 05, 2021 07:30 ET
|
InflaRx N.V.
Severe COVID-19 trial enrollment reaches 299 patients; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable...
InflaRx to Present at the Raymond James Human Health Innovation Conference
June 17, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
June 08, 2021 07:30 ET
|
InflaRx N.V.
Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumab JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage...
Tony Gibney Joins InflaRx Board of Directors
May 21, 2021 07:30 ET
|
InflaRx N.V.
JENA, Germany, May 21, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports First Quarter 2021 Financial & Operating Results
May 12, 2021 07:30 ET
|
InflaRx N.V.
Severe COVID-19 trial enrollment reaches 178 patients; interim analysis expected in Q3 At the FDA’s suggestion, planning to request a Type A meeting to further discuss primary endpoint for the Phase...